Saponins and Chromans Derivatives Mixture Compositions against Leishmaniasis, Trypanosomiasis Americana, Malaria, Trypanosomiasis Africana and Fasciola Hepatica

More than 1 billion people in the world suffer from some neglected infectious disease, such as Leishmaniasis, Malaria, African Trypanosomiasis, or others. These diseases cause disfigurement, permanent disability and death. Leishmaniasis is endemic in approximately 98 countries and it is estimated that more than 350 million people are at risk. Each year, between 700,000 and one million new cases and between 20,000 and 30,000 deaths are reported. Current treatments have side effects such as nausea, vomiting, anorexia, lethargy, myalgia, toxicity and pancreatic disease. In addition, they require constant medical supervision, which increases costs for the patient. In response to this situation, the Program for the Study and Control of Tropical Diseases -PECET- of the University of Antioquia, developed a cream formulation with Amphotericin B, a compound that has proven activity against different species of Leishmania. Anfoleish is designed to treat cutaneous Leishmaniasis after topical application 2 or 3 times a day for 30 days.